BridgeBio Pharma BBIO Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EquityMethodInvestments.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's equity method investments?
- BridgeBio Pharma (BBIO) reported equity method investments of $61.53M in Q1 2026.
- How has BridgeBio Pharma's equity method investments changed year-over-year?
- BridgeBio Pharma's equity method investments decreased by 52.0% year-over-year, from $128.19M to $61.53M.
- What does equity method investments mean?
- Investments in other companies where the firm has significant influence but not total control.
- How do you interpret equity method investments?
- Growth in this balance reflects successful strategic partnerships or the expansion of the company's collaborative ecosystem.
- How does equity method investments compare across companies?
- Common in biotech for companies engaged in joint ventures or co-development agreements.